Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 2Suspended 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 28Pancreatic Neoplasms 17Stomach Neoplasms 13Carcinoma, Hepatocellular 13Breast Neoplasms 8Rectal Neoplasms 7Neoplasms 7Esophageal Neoplasms 7Colonic Neoplasms 7Carcinoma, Non-Small-Cell Lung 5Prostatic Neoplasms 4Cholangiocarcinoma 4Neoplasm Metastasis 3Lung Neoplasms 3Endometrial Neoplasms 3Diabetes Mellitus 3Crohn Disease 3Carcinoma, Renal Cell 3Uterine Cervical Neoplasms 2Triple Negative Breast Neoplasms 2Peritoneal Neoplasms 2Ovarian Neoplasms 2Multiple Sclerosis 2Multiple Myeloma 2Melanoma 2Liver Neoplasms 2Irritable Bowel Syndrome 2Head and Neck Neoplasms 2Gastrointestinal Stromal Tumors 2Gastrointestinal Neoplasms 2

Interventions

Immunotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Suspended × Biliary Tract Carcinoma × Gastrointestinal × Clear all
NCT06199882 2024-10-15

SBRT Sequential Surufatinib Combined With Immunotherapy for Biliary Tract Carcinoma

Zhejiang Cancer Hospital

Phase 2 Suspended
34 enrolled
Gastrointestinal

Biliary Tract Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡